Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MMP9 | P14780 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | APLNR | P35414 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28628306 | 0.82 | LMNA (0.40) | USP2TSHRALDH1A1KDM4ELMNA | |
| SCHEMBL12191568 | 0.81 | ALDH1A1 (0.32) | USP2TSHRALDH1A1KDM4ELMNA | |
| SCHEMBL4505170 | 0.79 | LTA4H (0.45) | TSHRKDM4ELMNA | |
| SCHEMBL4504046 | 0.79 | CNR2 (0.48) | TSHRALDH1A1LMNAALOX15 | |
| SCHEMBL795481 | 0.78 | USP2 (0.50) | USP2TSHRALDH1A1KDM4ELMNA | |
| SCHEMBL4499222 | 0.78 | SMN1; SMN2 (0.51) | TSHRALDH1A1LMNAAPLNR | |
| SCHEMBL16451224 | 0.77 | PER2 (0.42) | USP2TSHRALDH1A1APLNR | |
| SCHEMBL14497716 | 0.77 | USP2 (0.55) | USP2TSHRALDH1A1KDM4ELMNA | |
| SCHEMBL2077476 | 0.77 | TSHR (0.55) | USP2TSHRALDH1A1KDM4ELMNA | |
| SCHEMBL22345342 | 0.75 | CA12 (0.36) | USP2TSHRALDH1A1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3110793-B1 | SULFONAMIDE AND SULFINAMIDE PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES | ALKERMES PHARMA IRELAND LTD (IE) | 2019-08-21 | — | — | EP | disclosed |
| EP-3110793-B1 | SULFONAMIDE AND SULFINAMIDE PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES | ALKERMES PHARMA IRELAND LTD (IE) | 2019-08-21 | — | — | EP | disclosed |
| US-10301256-B2 | Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases | ALKERMES PHARMA IRELAND LIMITED (IE) | 2019-05-28 | — | — | US | disclosed |
| US-10301256-B2 | Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases | ALKERMES PHARMA IRELAND LIMITED (IE) | 2019-05-28 | — | — | US | disclosed |
| US-20170129851-A1 | SULFONAMIDE AND SULFINAMIDE PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2017-05-11 | — | — | US | disclosed |
| US-20170129851-A1 | SULFONAMIDE AND SULFINAMIDE PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2017-05-11 | — | — | US | disclosed |
| US-20170129851-A1 | SULFONAMIDE AND SULFINAMIDE PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2017-05-11 | — | — | US | disclosed |
| US-9604922-B2 | Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases | ALKERMES PHARMA IRELAND LIMITED (IE) | 2017-03-28 | — | — | US | disclosed |
| US-9604922-B2 | Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases | ALKERMES PHARMA IRELAND LIMITED (IE) | 2017-03-28 | — | — | US | disclosed |
| US-9604922-B2 | Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases | ALKERMES PHARMA IRELAND LIMITED (IE) | 2017-03-28 | — | — | US | disclosed |
| EP-3110793-A1 | SULFONAMIDE AND SULFINAMIDE PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES | Alkermes Pharma Ireland Limited (IE) | 2017-01-04 | — | — | EP | disclosed |
| US-20150239829-A1 | SULFONAMIDE AND SULFINAMIDE PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2015-08-27 | — | — | US | disclosed |
| US-20150239829-A1 | SULFONAMIDE AND SULFINAMIDE PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2015-08-27 | — | — | US | disclosed |
| US-20150239829-A1 | SULFONAMIDE AND SULFINAMIDE PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2015-08-27 | — | — | US | disclosed |
| WO-2015127450-A1 | SULFONAMIDE AND SULFINAMIDE PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES | ALKERMES PHARMA IRELAND LIMITED (IE) | 2015-08-27 | — | — | WO | disclosed |
| US-7314959-B2 | Amino thiol compounds and compositions for use in conjunction with cancer therapy | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2008-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10301256-B2 | Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases | SULT2A1, FH, STS | USP2 1289/4885TSHR 3365/4885ALDH1A1 1312/4885 |
| US-20170129851-A1 | SULFONAMIDE AND SULFINAMIDE PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES | SULT2A1, FH, STS | USP2 1289/4885TSHR 3365/4885ALDH1A1 1312/4885 |
| US-20150239829-A1 | SULFONAMIDE AND SULFINAMIDE PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES | SULT2A1, FH, STS | USP2 1289/4885TSHR 3365/4885ALDH1A1 1312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.